YMTX Yumanity Therapeutics, Inc.

Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform allows the Company to rapidly screen for disease-modifying therapies to overcome toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s growing pipeline consists of additional programs focused on dementia with Lewy bodies, amyotrophic lateral sclerosis (ALS), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease.

$8.98
As of 07/23/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/11/2016
Outstanding shares:  10,202,506
Average volume:  83,132
Market cap:   $91,618,504
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98872L102
ISIN:        US98872L1026
Sedol:      BN4J3J3
Valuation   (See tab for details)
PE ratio:   -2.37
PB ratio:   1.87
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy